Independent
Tenure on this board
2.3 yrs
Also a director at
Mineralys Therapeutics Inc (MLYS)Scholar Rock Holding Corp (SRRK)Vtv Therapeutics Inc (VTVT)Kalaris Therapeutics Inc (KLRS)
Meeting calendar
ALMS · Annual meeting · Wednesday, July 30, 2025
Alumis Inc
2 nominees · 2 ballot items.
Election of two Class I directors to the board (Proposal 1) and ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025 (Proposal 2).
Market cap
$3.4B
1Y TSR
+601.8%
Board grade
C+
Record date
Jun 4, 2025
Filing
DEF 14A
Meeting concluded · Jul 30, 2025
Follow how the vote landed and what changed on Alumis Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot2
- 1
Election of two Class I directors
ManagementBoard: FORElection of Srinivas Akkaraju, M.D., Ph.D. and Sapna Srivastava, Ph.D. to serve as Class I directors until the 2028 Annual Meeting and until their successors are duly elected and qualified.
- 2
Ratification of appointment of independent registered public accounting firm
ManagementBoard: FORRatification of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025.
Director elections
Nominees on the ballot2
Independent
Tenure on this board
3.9 yrs
Also a director at
Nuvalent Inc (NUVL)Aura Biosciences Inc (AURA)
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | Deep Track Capital, LP | 5.3% | 6,772,595 | $149M |
| 2 | Samsara BioCapital, LLC | 5.0% | 6,345,219 | $140M |
| 3 | Foresite Capital Management V, LLC | 4.6% | 5,896,995 | $130M |
| 4 | venBio Partners LLC | 3.6% | 4,528,408 | $100M |
| 5 | Foresite Capital Management VI LLC | 3.3% | 4,247,670 | $94M |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 3.2% | 4,032,266 | $89M |
| 7 | Cormorant Asset Management, LP | 3.1% | 3,949,241 | $87M |
| 8 | Nextech Invest, Ltd. | 2.8% | 3,540,998 | $78M |
| 9 | BlackRock, Inc. | 2.6% | 3,350,946 | $74M |
| 10 | Saturn V Capital Management LP | 2.5% | 3,202,075 | $71M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Alumis Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Haemonetics CorpHAE
Annual meeting·Jul 24, 2026·$3.4B
Organon & CoOGN
Special meeting·Jul 23, 2026·$3.6B
Catalyst Pharmaceuticals IncCPRX
Special meeting·Jul 8, 2026·$3.8B
Prestige Consumer Healthcare IncPBH
Annual meeting·Aug 4, 2026·$2.2B
Anaptysbio IncANAB
Annual meeting·Aug 11, 2026·$2.0B
Trulieve Cannabis CorpTRLV
Special meeting·Aug 5, 2026·$1.9B
Reference
Frequently asked questions
- When is the Alumis Inc 2025 annual meeting?
- Alumis Inc (ALMS) holds its 2025 annual shareholder meeting on Wednesday, July 30, 2025.
- What is the record date for the Alumis Inc 2025 meeting?
- The record date for the Alumis Inc 2025 meeting is Wednesday, June 4, 2025. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Alumis Inc's 2025 meeting?
- The board is presenting 2 director nominees at the Alumis Inc 2025 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Alumis Inc 2025 meeting?
- Shareholders will vote on 2 proposals at the Alumis Inc 2025 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.